Edgewise Therapeutics, Inc. — Form 8-K/A
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 78/100
What the filing says
On July 10, 2026, Edgewise completed the sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion upfront cash plus up to $1.1 billion in regulatory/commercial milestones (total potential $2.65 billion). The transaction generated an estimated $1.488 billion pretax gain ($1.262 billion after-tax). Post-transaction, Edgewise pivots to a cardiovascular-focused company with pipeline programs EDG-7500, EDG-15400, and EDG-003. The company will provide transition services to Servier at 50% cost reimbursement for at least 18 months.
Why this rating
Upfront proceeds ($1.55B) equal 129% of company market cap; transforms capital structure and business focus. Significant but not going-concern-level—company retains operations and cash runway.
Extracted items
- 2.01 acquisition/disposition
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.